Danish maker of obesity drugs to replace Lars Fruergaard Jørgensen, saying new leadership is needed as shares slump 50% in ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...

Pedersen and Stine Jacobsen COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday ...

Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 and was appointed chief executive officer in January 2017. During his ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Lars Fruergaard Jørgensen is stepping down as Novo Nordisk CEO, with the company citing its stock's recent struggles.

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...